RESUMO
There is no doubt that navigating academia is a formidable challenge, particularly for those from underrepresented backgrounds who face additional barriers at every turn. In such an environment, efforts to create learning and training environments that are diverse, equitable, and inclusive can feel like an uphill battle. We believe that harnessing the power of artificial intelligence (AI) tools can help in leveling the playing field. While AI cannot supplant the need for supportive mentorship, it can serve as a vital supplement, offering guidance and assistance to those who may lack access to adequate avenues of support. Embracing AI in this context should not be stigmatized, as it may represent a vital lifeline for underrepresented individuals who often face systemic biases while forging their own paths in pursuit of success and belonging in academia. AI tools should not be gatekept from these individuals, particularly by those in positions of power and privilege within the scientific community. Instead, we argue, institutions should make a strong commitment to educating their community members on how to ethically harness these tools.
Assuntos
Inteligência Artificial , Aprendizagem , Humanos , Grupo Associado , Comunicação , MentoresRESUMO
COVID-19 pandemic created a turmoil across nations due to Severe Acute Respiratory Syndrome Corona virus-1(SARS - Co-V-2). The severity of COVID-19 symptoms is starting from cold, breathing problems, issues in respiratory system which may also lead to life threatening situations. This disease is widely contaminating and transmitted from man-to-man. The contamination is spreading when the human organs like eyes, nose, and mouth get in contact with contaminated fluids. This virus can be screened through performing a nasopharyngeal swab test which is time consuming. So the physicians are preferring the fast detection methods like chest radiography images and CT scans. At times some confusion in finding out the accurate disorder from chest radiography images can happen. To overcome this issue this study reviews several deep learning and machine learning procedures to be implemented in X-ray images of chest. This also helps the professionals to find out the other types of malfunctions happening in the chest other than COVID-19 also. This review can act as a guidance to the doctors and radiologists in identifying the COVID-19 and other types of viruses causing illness in the human anatomy and can provide aid soon.
Assuntos
Inteligência Artificial , COVID-19 , Humanos , COVID-19/diagnóstico por imagem , Pandemias , Raios X , Radiografia , Teste para COVID-19RESUMO
Infertility has massively disrupted social and marital life, resulting in stressful emotional well-being. Early diagnosis is the utmost need for faster adaption to respond to these changes, which makes possible via AI tools. Our main objective is to comprehend the role of AI in fertility detection since we have primarily worked to find biomarkers and related risk factors associated with infertility. This paper aims to vividly analyse the role of AI as an effective method in screening, predicting for infertility and related risk factors. Three scientific repositories: PubMed, Web of Science, and Scopus, are used to gather relevant articles via technical terms: (human infertility OR human fertility) AND risk factors AND (machine learning OR artificial intelligence OR intelligent system). In this way, we systematically reviewed 42 articles and performed a meta-analysis. The significant findings and recommendations are discussed. These include the rising importance of data augmentation, feature extraction, explainability, and the need to revisit the meaning of an effective system for fertility analysis. Additionally, the paper outlines various mitigation actions that can be employed to tackle infertility and its related risk factors. These insights contribute to a better understanding of the role of AI in fertility analysis and the potential for improving reproductive health outcomes.
Assuntos
Inteligência Artificial , Infertilidade , Humanos , Fertilidade , Emoções , Aprendizado de MáquinaRESUMO
Industrial artificial intelligence (IAI) and other analysis tools with obfuscated internal processes are growing in capability and ubiquity within industrial settings. Decision-makers share their concern regarding the objective evaluation of such tools and their impacts at the system level, facility level, and beyond. One application where this style of tool is making a significant impact is in Condition Monitoring Systems (CMSs). This paper addresses the need to evaluate CMSs, a collection of software and devices that alert users to changing conditions within assets or systems of a facility. The presented evaluation procedure uses CMSs as a case study for a broader philosophy evaluating the impacts of IAI tools. CMSs can provide value to a system by forewarning faults, defects, or other unwanted events. However, evaluating CMS value through scenarios that did not occur is rarely easy or intuitive. Further complicating this evaluation are the ongoing investment costs and risks posed by the CMS from imperfect monitoring. To overcome this, an industrial facility needs to regularly and objectively review CMS impacts to justify investments and maintain competitive advantage. This paper's procedure assesses the suitability of a CMS for a system in terms of risk and investment analysis. This risk-based approach uses the changes in the likelihood of good and bad events to quantify CMS value without making any one-time point-wise estimates. Fictional case studies presented in this paper illustrate the procedure and demonstrate its usefulness and validity.
RESUMO
Introduction: As Artificial Intelligence (AI) technology continues to assimilate into various industries, there is a huge scope in the healthcare industry specifically in clinical laboratories. The perspective of the laboratory professionals can give valuable insight on the ideal path to take for AI implementation. Methods: The study utilized a cross-sectional survey design and was conducted at the section of Chemical Pathology, Department of Pathology and Laboratory Medicine, the Aga Khan University (AKU), Karachi, Pakistan in collaboration with Consultant Pathologists of 9 clinical laboratories associated with teaching hospitals across Pakistan from October-November 2023. The survey was for a duration of 2 weeks and was circulated to all working laboratory technical staff after informed consent. Results: A total of 351 responses were received, of which 342 (male=146, female=196) responses were recorded after exclusion. Respondents ranged from technologists, faculty, residents, and coordinators, and were from different sections (chemical pathology, microbiology, haematology, histopathology, POCT). Out of the total 312 (91.2%) of respondents stated that they were at least somewhat familiar with AI technology. Experts in AI were only 2.0% (n=7) of all respondents, but 90% (n=6) of these were < 30 years old. 76.3% (n=261) of the respondents felt the need to implement more AI technology in the laboratories, with time saving (26.1%) and improving performances of tests (17.7%) cited to be the greatest benefits of AI. Security concerns (n=144) and a fear of decreasing personal touch (n=143) were the main concerns of the respondents while the younger employees had an increased fear of losing their jobs. 76.3% were in favour of an increase in AI usage in the laboratories. Conclusion: This study highlights a favourable perspective among laboratory professionals, acknowledging the potential of AI to enhance both the efficiency and quality of laboratory practices. However, it underscores the importance of addressing their concerns in the thoughtful implementation of this emerging technology.
RESUMO
Purpose: Errors in the identification of true patients in a health-care facility may result in the wrong dose or dosage being given to the wrong patient at the wrong site during radiotherapy sessions, radiopharmaceutical administration, radiological scans, etc. The aim of this article is to reduce the error in the identification of correct patients by implementation of the Python deep learning-based real-time patient identification program. Materials and Methods: The authors utilized and installed Anaconda Prompt (miniconda 3), Python (version 3.9.12), and Visual Studio Code (version 1.71.0) for the design of the patient identification program. In the field of view, the area of interest is merely face detection. The overall performance of the developed program is accomplished over three steps, namely image data collection, data transfer, and data analysis, respectively. The patient identification tool was developed using the OpenCV library for face recognition. Results: This program provides real-time patient identification information, together with the other preset parameters such as disease site, with a precision of 0.92%, recall rate of 0.80%, and specificity of 0.90%. Furthermore, the accuracy of the program was found to be 0.84%. The output of the in-house developed program as "Unknown" is provided if a patient's relative or an unknown person is found in restricted region. Interpretation and Conclusions: This Python-based program is beneficial for confirming the patient's identity, without manual interventions, just before therapy, administering medications, and starting other medical procedures, among other things, to prevent unintended medical and health-related complications that may arise as a result of misidentification.
RESUMO
The nanotechnology-driven industrial revolution widely relies on metal oxide-based nanomaterial (NM). Zinc oxide (ZnO) production has rapidly increased globally due to its outstanding physical and chemical properties and versatile applications in industries including cement, rubber, paints, cosmetics, and more. Nevertheless, releasing Zn2+ ions into the environment can profoundly impact living systems and affect water-based ecosystems, including biological ones. In aquatic environments, Zn2+ ions can change water properties, directly influencing underwater ecosystems, especially fish populations. These ions can accumulate in fish tissues when fish are exposed to contaminated water and pose health risks to humans who consume them, leading to symptoms such as nausea, vomiting, and even organ damage. To address this issue, safety of ZnO NMs should be enhanced without altering their nanoscale properties, thus preventing toxic-related problems. In this study, an eco-friendly precipitation method was employed to prepare ZnO NMs. These NMs were found to reduce ZnO toxicity levels by incorporating elements such as Mg, Ca, Sr, and Ba. Structural, morphological, and optical properties of synthesized NMs were thoroughly investigated. In vitro tests demonstrated potential antioxidative properties of NMs with significant effects on free radical scavenging activities. In vivo, toxicity tests were conducted using Oreochromis mossambicus fish and male Swiss Albino mice to compare toxicities of different ZnO NMs. Fish and mice exposed to these NMs exhibited biochemical changes and histological abnormalities. Notably, ZnCaO NMs demonstrated lower toxicity to fish and mice than other ZnO NMs. This was attributed to its Ca2+ ions, which could enhance body growth metabolism compared to other metals, thus improving material safety. Furthermore, whether nanomaterials' surface roughness might contribute to their increased toxicity in biological systems was investigated utilizing computer vision (CV)-based AI tools to obtain SEM images of NMs, providing valuable image-based surface morphology data that could be correlated with relevant toxicology studies.
Assuntos
Nanoestruturas , Poluentes Químicos da Água , Óxido de Zinco , Humanos , Masculino , Animais , Camundongos , Óxido de Zinco/toxicidade , Óxido de Zinco/química , Inteligência Artificial , Ecossistema , Poluentes Químicos da Água/toxicidade , Nanoestruturas/toxicidade , Óxidos , ÁguaRESUMO
BACKGROUND: Primary care physicians are at the forefront of the clinical process that can lead to diagnosis, referral, and treatment. With electronic medical records (EMRs) being introduced and, over time, gaining acceptance by primary care users, they have now become a standard part of care. EMRs have the potential to be further optimized with the introduction of artificial intelligence (AI). There has yet to be a widespread exploration of the use of AI in primary health care and how clinicians envision AI use to encourage further uptake. OBJECTIVE: The primary objective of this research is to understand if the user-centered design approach, rooted in contextual design, can lead to an increased likelihood of adoption of an AI-enabled encounter module embedded in a primary care EMR. In this study, we use human factor models and the technology acceptance model to understand the results. METHODS: To accomplish this, a partnership has been established with an industry partner, TELUS Health, to use their EMR, the collaborative health record. The overall intention is to understand how to improve the user experience by using user-centered design to inform how AI should be embedded in an EMR encounter. Given this intention, a user-centered approach will be used to accomplish it. The approach of user-centered design requires qualitative interviewing to gain a clear understanding of users' approaches, intentions, and other key insights to inform the design process. A total of 5 phases have been designed for this study. RESULTS: As of March 2024, a total of 14 primary care clinician participants have been recruited and interviewed. First-cycle coding of all qualitative data results is being conducted to inform redesign considerations. CONCLUSIONS: Some limitations need to be acknowledged related to the approach of this study. There is a lack of market maturity of AI-enabled EMR encounters in primary care, requiring research to take place through scenario-based interviews. However, this participant group will still help inform design considerations for this tool. This study is targeted for completion in the late fall of 2024. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/54365.
Assuntos
Inteligência Artificial , Registros Eletrônicos de Saúde , Atenção Primária à Saúde , Design Centrado no Usuário , Humanos , Atenção Primária à Saúde/organização & administração , CanadáRESUMO
The article examines the impact of artificial intelligence on scientific writing, with a particular focus on its application in hospital pharmacy. It analyzes artificial intelligence tools that enhance information retrieval, literature analysis, writing quality, and manuscript drafting. Chatbots like Consensus, along with platforms such as Scite and SciSpace, enable precise searches in scientific databases, providing evidence-based responses and references. SciSpace facilitates the generation of comparative tables and the formulation of queries regarding studies, while ResearchRabbit maps the scientific literature to identify trends. Tools like DeepL and ProWritingAid improve writing quality by correcting grammatical, stylistic, and plagiarism errors. A.R.I.A. enhances reference management, and Jenny AI assists in overcoming writer's block. Python libraries such as LangChain enable advanced semantic searches and the creation of agents. Despite their benefits, artificial intelligence raises ethical concerns including biases, misinformation, and plagiarism. The importance of responsible use and critical review by experts is emphasized. In hospital pharmacy, artificial intelligence can enhance efficiency and precision in research and scientific communication. Pharmacists can use these tools to stay updated, enhance the quality of their publications, optimize information management, and facilitate clinical decision-making. In conclusion, artificial intelligence is a powerful tool for hospital pharmacy, provided it is used responsibly and ethically.
RESUMO
As artificial intelligence (AI) models improve and become widely integrated into healthcare systems, healthcare providers must understand the strengths and limitations of AI tools to realize the full spectrum of potential patient-care benefits. However, most providers have a poor understanding of AI, leading to distrust and poor adoption of this emerging technology. To bridge this divide, this editorial presents a novel view of ChatGPT's current capabilities in the medical field of radiation oncology. By replicating the format of the oral qualification exam required for radiation oncology board certification, we demonstrate ChatGPT's ability to analyze a commonly encountered patient case, make diagnostic decisions, and integrate information to generate treatment recommendations. Through this simulation, we highlight ChatGPT's strengths and limitations in replicating human decision-making in clinical radiation oncology, while providing an accessible resource to educate radiation oncologists on the capabilities of AI chatbots.
RESUMO
Background: Despite immense progress in artificial intelligence (AI) models, there has been limited deployment in health care environments. The gap between potential and actual AI applications is likely due to the lack of translatability between controlled research environments (where these models are developed) and clinical environments for which the AI tools are ultimately intended. Objective: We previously developed the Translational Evaluation of Healthcare AI (TEHAI) framework to assess the translational value of AI models and to support successful transition to health care environments. In this study, we applied the TEHAI framework to the COVID-19 literature in order to assess how well translational topics are covered. Methods: A systematic literature search for COVID-19 AI studies published between December 2019 and December 2020 resulted in 3830 records. A subset of 102 (2.7%) papers that passed the inclusion criteria was sampled for full review. The papers were assessed for translational value and descriptive data collected by 9 reviewers (each study was assessed by 2 reviewers). Evaluation scores and extracted data were compared by a third reviewer for resolution of discrepancies. The review process was conducted on the Covidence software platform. Results: We observed a significant trend for studies to attain high scores for technical capability but low scores for the areas essential for clinical translatability. Specific questions regarding external model validation, safety, nonmaleficence, and service adoption received failed scores in most studies. Conclusions: Using TEHAI, we identified notable gaps in how well translational topics of AI models are covered in the COVID-19 clinical sphere. These gaps in areas crucial for clinical translatability could, and should, be considered already at the model development stage to increase translatability into real COVID-19 health care environments.
RESUMO
BACKGROUND: The promise of artificial intelligence (AI) to transform health care is threatened by a tangle of challenges that emerge as new AI tools are introduced into clinical practice. AI tools with high accuracy, especially those that detect asymptomatic cases, may be hindered by barriers to adoption. Understanding provider needs and concerns is critical to inform implementation strategies that improve provider buy-in and adoption of AI tools in medicine. OBJECTIVE: This study aimed to describe provider perspectives on the adoption of an AI-enabled screening tool in primary care to inform effective integration and sustained use. METHODS: A qualitative study was conducted between December 2019 and February 2020 as part of a pragmatic randomized controlled trial at a large academic medical center in the United States. In all, 29 primary care providers were purposively sampled using a positive deviance approach for participation in semistructured focus groups after their use of the AI tool in the randomized controlled trial was complete. Focus group data were analyzed using a grounded theory approach; iterative analysis was conducted to identify codes and themes, which were synthesized into findings. RESULTS: Our findings revealed that providers understood the purpose and functionality of the AI tool and saw potential value for more accurate and faster diagnoses. However, successful adoption into routine patient care requires the smooth integration of the tool with clinical decision-making and existing workflow to address provider needs and preferences during implementation. To fulfill the AI tool's promise of clinical value, providers identified areas for improvement including integration with clinical decision-making, cost-effectiveness and resource allocation, provider training, workflow integration, care pathway coordination, and provider-patient communication. CONCLUSIONS: The implementation of AI-enabled tools in medicine can benefit from sensitivity to the nuanced context of care and provider needs to enable the useful adoption of AI tools at the point of care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04000087; https://clinicaltrials.gov/ct2/show/NCT04000087.
RESUMO
PURPOSE: Despite tremendous gains from deep learning and the promise of artificial intelligence (AI) in medicine to improve diagnosis and save costs, there exists a large translational gap to implement and use AI products in real-world clinical situations. Adoption of standards such as Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis, Consolidated Standards of Reporting Trials, and the Checklist for Artificial Intelligence in Medical Imaging is increasing to improve the peer-review process and reporting of AI tools. However, no such standards exist for product-level review. METHODS: A review of clinical trials showed a paucity of evidence for radiology AI products; thus, the authors developed a 10-question assessment tool for reviewing AI products with an emphasis on their validation and result dissemination. The assessment tool was applied to commercial and open-source algorithms used for diagnosis to extract evidence on the clinical utility of the tools. RESULTS: There is limited technical information on methodologies for FDA-approved algorithms compared with open-source products, likely because of intellectual property concerns. Furthermore, FDA-approved products use much smaller data sets compared with open-source AI tools, because the terms of use of public data sets are limited to academic and noncommercial entities, which precludes their use in commercial products. CONCLUSIONS: Overall, this study reveals a broad spectrum of maturity and clinical use of AI products, but a large gap exists in exploring actual performance of AI tools in clinical practice.